Skip to main content

Advertisement

Table 2 Summary of Subject Follow-up

From: Time courses of improvement and symptom remission in children treated with atomoxetine for attention-deficit/hyperactivity disorder: analysis of Canadian open-label studies

  Study
  LYCS S012 S013 All
Weeks From Baseline to Last ADHDRS-IV-PI Assessment
   N† 102 198 20 320
   Mean (SE) 42.7 (1.63) 11.5 (0.23) 22.5 (1.64) 22.2 (0.97)
   Median 51.3 12.9 25.9 13.3
   Range 3.9-58.0 1.0-17.3 4.4-27.1 1.0-58.0
Weeks From Baseline to Last CGI-ADHD-S Assessment
   N† 102 206 21 329
   Mean (SE) 43.1 (0.15) 11.2 (0.25) 21.5 (1.9) 21.7 (0.96)
   Median 51.3 12.7 25.9 13.3
   Range 2.3-58.0 1.0-17.3 1.6-27.1 1.0-58.0
  1. †Only study participants with both a baseline value and at least one post-baseline value were included in this summary.
  2. ADHDRS-IV-PI = Attention-Deficit/Hyperactivity Disorder Rating Scale Parent Version: Investigator Administered and Scored; CGI-ADHD-S = Clinical Global Impression of ADHD Severity.